Mounjaro
(Tirzepatide)ApprovedPeptide
Eli LillyTirzepatide is used to help people with type 2 diabetes control their blood sugar levels, and it's also used for weight loss in people who are overweight or obese.[2] Mounjaro is currently approved and in use across 48 indications[4].[1]
Mounjaro is one of 988 peptide programs targeting Coronary Artery Disease. It is currently in Approved.
48
Indications
183
Total Trials
118
Active Trials
987
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
10
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 48 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Mounjaro
Eli LillyApproved
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Voltaren
NovartisPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity34 trials
Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity
Not yet recruiting·—·N/A·NCT07319975·48 enrolled
Show 31 more trials
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07293325·66 enrolled
Anti-obesity Pharmacotherapy and Inflammation
Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled
Tirzepatide for Obesity and Meth Use Disorder
Active, not recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06745128·45 enrolled
A Multicenter Randomized Controlled Trial Evaluating AI-Assisted Intensive Lifestyle Intervention Versus Tirzepatide for Glycemic and Weight Management in Patients With Obesity and Newly Diagnosed Type 2 Diabetes
Not yet recruiting·TThe First Affiliated Hospital of Anhui Medical University·Approved·NCT07697391·285 enrolled
Type 2 Diabetes29 trials
Show 26 more trials
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
Active, not recruiting·—··NCT06980623·26,000 enrolled
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Active, not recruiting·—··NCT06779929·70,000 enrolled
Overweight19 trials
Show 16 more trials
Type 2 Diabetes Mellitus9 trials
Show 6 more trials
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
Not yet recruiting·—··NCT07099742·364 enrolled
Type 1 Diabetes7 trials
Show 4 more trials
60 more indications
Endometrial Cancer4 trials
ART4 trials
Breast Cancer3 trials
Heart Failure3 trials
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
Completed·—··NCT06914141·28,118 enrolled
Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
Completed·—··NCT06914154·11,265 enrolled
GLP-13 trials
Bariatric Surgery3 trials
Psoriatic Arthritis3 trials
Obese2 trials
Atrial Fibrillation2 trials
Female2 trials
Cardiovascular2 trials
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
Completed·—··NCT07088718·44,671 enrolled
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Completed·—··NCT07096063·887,132 enrolled
Function2 trials
Prostate Cancer2 trials
Cannabis Use Disorder2 trials
Tirzepatide for the Treatment of Cannabis Use Disorder
Not yet recruiting·—·Phase 2·NCT07265752·6 enrolled
Cardiovascular Disease1 trial
Coronary Artery Disease1 trial
Inflammatory Bowel Disease1 trial
Eating Disorder1 trial
Body Weight1 trial
Chronic Kidney Disease1 trial
Intracranial Hypertension1 trial
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Not yet recruiting·—·Phase 4·NCT07191873·60 enrolled
Effectiveness1 trial
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 3·NCT06246799·256 enrolled
Obstructive Sleep Apnea1 trial
Semaglutide1 trial
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
Not yet recruiting·—·Phase 4·NCT07483801·112 enrolled
Metabolic Disease1 trial
Hypertension1 trial
ALD1 trial
Tirzepatide in MetALD
Not yet recruiting·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 2·NCT07046819·120 enrolled
Coronary Atherosclerosis1 trial
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Recruiting·—·Phase 4·NCT05708859·120 enrolled
Osteoarthritis1 trial
Motor Function1 trial
Adult1 trial
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT06811324·20 enrolled
Colorectal Tumors1 trial
Opioid Use Disorder1 trial
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Recruiting·—·Phase 2·NCT06651177·310 enrolled
Efficacy and Safety1 trial
Efficacy and Safety of Tirzepatide for Weight Management
Active, not recruiting·—·Phase 3·NCT06918405·440 enrolled
Hidradenitis Suppurativa1 trial
Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa
Not yet recruiting·—·N/A·NCT06301256·20 enrolled
Schizophrenia1 trial
Weight loss1 trial
Mortality1 trial
Alcohol Use Disorder (AUD)1 trial
Obesity and Overweight1 trial
Hormone-receptor-positive Breast Cancer1 trial
Ulcerative Colitis1 trial
Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial
Mild Autonomous Cortisol Secretion (MACS)1 trial
Cannabis Use1 trial
Regulatory
FDA Approval Timeline[5]
Jul 28, 2023
MOUNJARO
NDA NDA215866
Mar 28, 2024
ZEPBOUND
NDA NDA217806
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Mounjaro drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Tirzepatide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
- [8]